drugset / Trial / NCT00625573
Phase II Trial of Abraxane and Capecitabine in Metastatic Colon Cancer (COL 01)
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, phase II study to evaluate the efficacy and safety of Abraxane in combination with Capecitabine in patients with metastatic colorectal cancer in the second or third line
Timeline
- Start
- 2007-09
- Primary completion
- 2009-02
- Completion
- 2009-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abraxane | Small molecule | 100 mg/m2 | — |